Pharmacia TNF-Inhibitor’s Monthly Dosing Could Offer Marketing Advantage
Executive Summary
Pharmacia's experimental tumor necrosis factor inhibitor CDP-870 could gain a competitive advantage through a once-monthly dosing schedule
You may also be interested in...
Amgen Enbrel Projections Include 3-Month Cushion For Immunex Plant
Amgen's financial forecasts for the Immunex acquisition include a three-month cushion on the start-up date for a new production plant for Enbrel.
Amgen Enbrel Projections Include 3-Month Cushion For Immunex Plant
Amgen's financial forecasts for the Immunex acquisition include a three-month cushion on the start-up date for a new production plant for Enbrel.
Pharmacia Bextra Promotions Could Emphasize Rapid Onset Of Action
Pharmacia's promotion strategy for Bextra (valdecoxib) appears to be emphasizing the second generation COX-2 inhibitor's rapid onset of action